NSI Rising Stars in Immunology Seminar Series
The NSI Rising Stars in Immunology Seminar Series is a new NSI initiative this year (2021) that aims to invite young PIs from all over the world working on immunology.
Please send us your suggestions for future speakers! We are striving for a broad coverage of immunology topics, geographical locations as well as gender balance.
Send speaker suggestions to Victor Greiff: firstname.lastname@example.org
We are pleased to have Associate Professor Marco Donia (University of Copenhagen) for the 5th session of NSI Rising Stars in Immunology – see seminar details below:
Speaker: Associate Prof Marco Donia, MD, PhD
Title: Cancer Immunotherapy: merging research and real-world evidence
Date: Thursday, June 10, 14-15:00
Meeting ID: 621 0133 2011
Bio: Dr. Marco Donia is Clinician-Scientist (50% staff specialist and 50% junior research group leader), Center for Cancer Immune Therapy-CCIT, Department of Oncology, Copenhagen University Hospital Herlev, Denmark and a Clinical Associate Professor, Department of Clinical Medicine, University of Copenhagen, Denmark. List of publications. https://orcid.org/0000-0003-4966-9752. He is also a Lundbeck fellow with a project to identify and study the effect of the substances that stimulate cancer cells and to attempt to minimise their effect.
Previous NSI Rising Stars Meetings
Speaker: Prof Susan Rooijakkers, MD, PhD
‘Antibodies against bacterial infections: from basic insights to therapies’
Date: Thursday, May 20, 14-15:00
Bio: Prof Suzan Rooijakkers is head of the Bacterial Infections and Immunity. Suzan Rooijakkers is full professor at the Department of Medical Microbiology at the University Medical Center in Utrecht. She is an expert in the field of Bacterial Infections and Immunity. During her PhD and postdocs, Rooijakkers played an important role in the discovery of bacterial immune escape mechanisms. She identified several molecules secreted by S. aureus to modulate human complement and neutrophils (Nature Immunology (2005 & 2009), patent (2006), Journal of Experimental Medicine (2007), PNAS (2014)). After completing a postdoc at UCSD San Diego (USA), Rooijakkers established an independent research group focused at understanding the molecular interplay between bacteria and the human immune system, with the ultimate aim to translate research findings into new strategies for treatment of infectious disease. Her current research group (8 PhD students, 3 Postdocs and 1 technician) mainly focuses on the following main themes: How the human immune system kills bacteria and Antibody therapies against bacteria.
Speaker: Jeremy Swann
‘Adaptive disarmament: the immunogenetics of deep-sea anglerfish’
Date: Thursday, Feb 25 at 14.00.
[Bio: Dr. Swann obtained his PhD from the University of Melbourne under the supervision of Mark Smyth. He is a group leader at the MPI of Immunobiology and Epigenetics (Freiburg, Germany). His latest article is on The immunogenetics of sexual parasitism, https://science.sciencemag.org/content/369/6511/1608]
Speaker: Dr. Roger Geiger (https://www.geigerlab.org/)
‘Systems analyses of anti-tumor T cell responses’
Date: Thursday, Jan 28 at 14.00.
[Bio: Dr. Geiger obtained his PhD from the ETH Zürich under the supervision of Ari Helenius. He received postdoctoral training in immunology with Antonio Lanzavecchia and in proteomics with Matthias Mann. Since 2017 Roger is an independent group leader at the Institute for Research in Biomedicine, CH. His groups works mainly on T-cell metabolism. He was awarded an ERCStG in 2018. His latest article is on Dynamics in protein translation sustaining T cell preparedness, https://www.nature.com/articles/s41590-020-0714-5].
Speaker: María Casanova Acebes, PhD
‘Lineage tracing reveals the pro-tumorigenic niche role of tissue resident macrophages in early lung cancer lesions’
Date: Thursday, April 8 at 14.00
Dr. María Casanova Acebes is head of the Cancer Immunity Laboratory at www.cnio.es. She completed her postdoctoral training in the laboratory of Miriam Merad. Here latest work has been published in Nature Communications: https://www.nature.com/articles/s41467-020-15371-0: RXRs control serous macrophage neonatal expansion and identity and contribute to ovarian cancer progression.